IQVIA HOLDINGS INC (IQV)

IQV Stock Earnings: IQVIA Hldgs Beats EPS, Beats Revenue for Q1 2024

IQV stock results show that IQVIA Hldgs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

IQVIA Reports First-Quarter 2024 Results

Analysts Are Pounding the Table on These 3 Stocks: April 2024

From pharmaceutical testing to expansive integration expanding infrastructure, here are three stocks with analyst recommendations to buy.

IQVIA Celebrates Wendy Stewart and Susan Barnes, Winners of Healthcare Businesswoman's Association Luminary and Rising Star Awards

IQVIA to Announce First-Quarter 2024 Results on May 2, 2024

IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud

Williams Now #193 Largest Company, Surpassing IQVIA Holdings

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

Agree To Purchase IQVIA Holdings At $250, Earn 9% Annualized Using Options

IQVIA CFO Ron Bruehlman to Speak at Barclays Annual Global Healthcare Conference on March 13, 2024

IQVIA Publishes its 2023 Environmental, Social and Governance Report

Global Biopharma R&D Boasts Increased Funding, Productivity and Product Launches in 2023, says IQVIA Institute Report

IQVIA CFO Ron Bruehlman to Speak at Citi’s Unplugged Medtech and Life Sciences Access Day on February 29, 2024

Contract research firms gain after Q4 results (NYSE:IQV)

Shares of contract research organizations IQVIA Holdings (IQV) and Charles River Laboratories (CRL) gain as their Q4 results exceed expectations. Read more here.

IQVIA Reports Fourth-Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance

IQVIA Named to Fortune® World's Most Admired Companies™ List, Ranked #1 in Its Sector for the Third Consecutive Year

S&P 500 Analyst Moves: IQV

IQVIA to Announce Fourth-Quarter and Full-Year 2023 Results on February 14, 2024

Biogen stock slips as UBS downgrades (NASDAQ:BIIB)

Biogen (BIIB) stock traded lower after UBS downgraded it citing slower uptake for its Alzheimer's treatment Leqembi marketed with Eisai (ESALF) (ESAIY). Read more here.

Global Medicine Spending to Reach $2.3 Trillion by 2028 as More Patients Get Access to Better Therapies, Says IQVIA Institute Report

Stock leaders for 2030 in Health Tech - UBS (NYSE:IQV)

UBS' list of health tech stocks with opportunities for growth through 2030.

If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names

Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month.

Iqvia stock slips on legal setback for DeepIntent deal

Iqvia Holdings (IQV) faces setback in acquisition of DeepIntent after U.S. court upholds FTC's order to block the deal over antitrust concerns. Read more here.